HIV DIAGNOSTICS TEST MARKET ANALYSIS

HIV Diagnostics Test Market Size and Trends

The HIV Diagnostics Test Market is estimated to be valued at USD 4.44 Bn in 2024 and is expected to reach USD 8.24 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.2% from 2024 to 2031.

To learn more about this report, request sample copy

The market is expected to witness positive growth during the forecast period. Rapid expansion of healthcare investments and increasing awareness about HIV diagnosis are expected to boost market growth. In addition, rising initiatives by government and private organizations to spread awareness about HIV diagnosis and treatment is also expected to support the market growth during this period. However, costly diagnostics procedures and issues related to low accessibility in remote areas may hamper market growth.

Increasing global prevalence of HIV

The global prevalence of HIV has been steadily rising over the past few decades posing a significant risk to public health across the world. UNAIDS estimates that approximately 38 million people were living with HIV globally at the end of 2020, with new infections and AIDS-related deaths remaining unacceptably high in many regions. Sub-Saharan Africa in particular has borne the brunt of the epidemic where around 68% of all people living with HIV reside. While new infections and deaths from AIDS have declined significantly in some countries due to treatment scale-up, many nations still face severe challenges in diagnosing those unaware of their HIV status and linking them to effective care. According to WHO, in 2020, there were an estimated 1.5 million new HIV infections and 680,000 AIDS-related deaths worldwide.

While conventional HIV testing methods centered on laboratory-based immunoassays, recent years have witnessed significant advancements in rapid and point-of-care approaches. These innovative formats have played a transformative role in widening access to diagnostic services particularly in resource-constrained areas. Traditional testing involved sending blood samples to centralized laboratories for ELISA and Western blot analysis which could take days to provide results. This created barriers for timely diagnosis due to the need for multiple visits and loss to follow up. It was also challenging in remote communities with limited laboratory infrastructure.